Figure 6.

NF-κB is activated in patient-derived HNSCC cell lines and cisplatin resistance is reversed with IKKβ inhibition. A. IC₅₀ values of UMSCC-11A and UMSCC-11B cells were determined. Cells were treated with Cisplatin (0-100 μM) for 72 hours. Cell proliferation was measured through MTT Assay. IC₅₀ values were determined. B. Cell lysates from UMSCC-11A and UMSCC-11B cells were analyzed by western blots. C. Cells were treated with different doses of CompA for 2 hours, lysed and analyzed by western blots. D. UMSCC-11B cells were treated with CompA alone, Cisplatin alone, or CompA and Cisplatin as indicated for 48 hours and cell proliferation was measured by MTT assay. The results are representative of three independent experiments (*, P < 0.05). E. Cells were treated same with (C) for 48 hours and Caspase 3/7 activity was measured. The results are representative of three independent experiments (*, P < 0.05). F. Cells were treated same with (C) and the levels of cleaved caspase 3 and GAPDH. The results are representative of three independent experiments. G. Cells were treated with CompA, Cisplatin, or CompA and Cisplatin as indicated and colony formation was observed and the numbers of colony were counted. Each experiment was repeated three times.